Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.3c00203
Abstract: Isocitrate dehydrogenase (IDH) 1/2 gain-of-function variants catalyze the production of the oncometabolite 2-hydroxyglutarate and are validated targets for leukemia treatment. We report binding and inhibition studies on 13 IDH1/2 variant inhibitors, including clinical candidates and…
read more here.
Keywords:
inhibition selectivity;
binding affinity;
inhibition;
idh1 ... See more keywords